Vyvanse is the first and only medication approved to treat moderate to severe Binge Eating Disorder (B.E.D.) in adults. Vyvanse is not for weight loss. It is not known if Vyvanse is safe and effective for the treatment of obesity.
Medicine isn’t right for all adults with moderate to severe B.E.D., so be sure to have an open and honest conversation with your doctor. Together, you can determine the course of action that's right for you and your specific needs.
Vyvanse could help you get control of your moderate to severe B.E.D.Talk to your doctor
In two 12-week studies of adults who were diagnosed with moderate to severe B.E.D., Vyvanse was proven to reduce weekly binge days (a day with at least 1 binge episode).
At the end of both Study 1 and Study 2, adults with moderate to severe B.E.D. who took Vyvanse experienced, on average, significantly fewer binge days per week compared to those who took placebo. The change in binge days per week for adult patients with moderate to severe B.E.D. from the start of the study to the end was measured using a statistical measure called the LS-Mean.
*On average from the start of the 12-week study to its end.
Do not take Vyvanse if you are taking or have taken within the past 14 days an anti-depressant called a monoamine oxidase inhibitor (MAOI) or are sensitive to, allergic to, or had a reaction to other stimulant medications.
Concerned about side effects? Talk to your doctor. Learn more.
The same 2 studies also looked at obsessive binge eating thoughts and compulsive binge eating behaviors. A tool used by doctors called the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) measured Vyvanse compared to placebo.
†At the final visit of each of the 12-week studies.
In the 2 studies, doctors also rated patients as much improved or very much improved ("improved"), or not improved, using the Clinical Global Impressions-Improvement rating scale(CGI-I).
In the 2 studies, the percentage of patients who had no binge eating episodes in the last 4 weeks were measured. This was defined as a patient who experienced no binge eating episodes during the 4 weeks leading up to the patients’ last visit of the study. Patients taking Vyvanse were more likely to have no binge eating episodes during this 4-week time period compared to patients taking placebo.
In this study, patients who initially responded to Vyvanse had a longer time to relapse compared to those who were switched to placebo.
Relapse was defined as a worsening in both the number of binge eating days (2 or more per week for 2 consecutive weeks) and the symptom severity score determined by the healthcare provider.
Adverse events seen in this study were consistent with those seen in other studies of adult patients with moderate to severe B.E.D. on Vyvanse.